Repositioning Candidate Details
Candidate ID: | R0873 |
Source ID: | DB05792 |
Source Type: | investigational |
Compound Type: | small molecule |
Compound Name: | Arylacenamide |
Synonyms: | -- |
Molecular Formula: | C23H35Cl2N |
SMILES: | Cl.CCN(C\C=C/C1=CC(Cl)=C(C=C1)C1CCCCC1)C1CCCCC1 |
Structure: |
|
DrugBank Description: | Arylacenamide (SR31747) is a peripheral ligand that binds four proteins in human cells, i.e. SRBP-1, -2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities. |
CAS Number: | 132173-07-0 |
Molecular Weight: | 396.437 |
DrugBank Indication: | Investigated for use/treatment in cancer/tumors (unspecified), immunosuppressive, and prostate cancer. |
DrugBank Pharmacology: | -- |
DrugBank MoA: | SR31747 blocks proliferation of human lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-versus-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis. Besides these immunomodulatory activities, the molecule also inhibits the proliferation of various tumor cell lines in vitro in a time- and concentration-dependent manner. |
Targets: | HCG20471, isoform CRA_c |
Inclusion Criteria: | Therapeutic strategy associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
---|---|---|---|---|---|
S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
Diseases ID | DO ID | Disease Name | Definition | Class | |
---|---|---|---|---|---|
I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |